HUE061051T2 - Tasimelteon Smith-Magenis szindróma kezelésére - Google Patents

Tasimelteon Smith-Magenis szindróma kezelésére

Info

Publication number
HUE061051T2
HUE061051T2 HUE15766274A HUE15766274A HUE061051T2 HU E061051 T2 HUE061051 T2 HU E061051T2 HU E15766274 A HUE15766274 A HU E15766274A HU E15766274 A HUE15766274 A HU E15766274A HU E061051 T2 HUE061051 T2 HU E061051T2
Authority
HU
Hungary
Prior art keywords
tasimelteon
magenis syndrome
smith
treating
treating smith
Prior art date
Application number
HUE15766274A
Other languages
English (en)
Hungarian (hu)
Inventor
Christian Lavedan
Mihael Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54147267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE061051(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of HUE061051T2 publication Critical patent/HUE061051T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Processing Of Solid Wastes (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Led Device Packages (AREA)
HUE15766274A 2014-09-02 2015-08-29 Tasimelteon Smith-Magenis szindróma kezelésére HUE061051T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US201562169635P 2015-06-02 2015-06-02

Publications (1)

Publication Number Publication Date
HUE061051T2 true HUE061051T2 (hu) 2023-05-28

Family

ID=54147267

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15766274A HUE061051T2 (hu) 2014-09-02 2015-08-29 Tasimelteon Smith-Magenis szindróma kezelésére

Country Status (17)

Country Link
US (5) US10179119B2 (cg-RX-API-DMAC7.html)
EP (2) EP3188727B1 (cg-RX-API-DMAC7.html)
JP (3) JP6903571B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170048541A (cg-RX-API-DMAC7.html)
CN (2) CN106604726A (cg-RX-API-DMAC7.html)
AU (2) AU2015312252B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017003644A2 (cg-RX-API-DMAC7.html)
CA (2) CA2957588C (cg-RX-API-DMAC7.html)
DK (1) DK3188727T3 (cg-RX-API-DMAC7.html)
ES (1) ES2936833T3 (cg-RX-API-DMAC7.html)
FI (1) FI3188727T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230070T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061051T2 (cg-RX-API-DMAC7.html)
MX (1) MX386150B (cg-RX-API-DMAC7.html)
PT (1) PT3188727T (cg-RX-API-DMAC7.html)
SI (1) SI3188727T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016036619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007253701A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Melatonin agonist treatment
CA2957588C (en) * 2014-09-02 2021-08-31 Vanda Pharmaceuticals Inc. Tasimelteon for treating smith-magenis syndrome
CN112074268A (zh) * 2018-03-04 2020-12-11 万达制药公司 用他司美琼治疗疾病
JP2022500420A (ja) * 2018-09-12 2022-01-04 バンダ・ファーマシューティカルズ・インコーポレイテッドVanda Pharmaceuticals Inc. 睡眠又は睡眠後パフォーマンスの改善
KR102650321B1 (ko) 2019-12-13 2024-03-21 반다 파마슈티칼즈, 인코퍼레이티드. 액체 타시멜테온 제형 및 이의 사용 방법
TWI891877B (zh) 2020-08-27 2025-08-01 日商友華股份有限公司 檢查裝置
CA3229930A1 (en) * 2021-09-14 2023-03-23 Mihael Polymeropoulos Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU719994B2 (en) 1996-12-10 2000-05-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
AU2007253701A1 (en) 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Melatonin agonist treatment
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
EP2453891A1 (en) 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
JP2015509106A (ja) * 2012-01-26 2015-03-26 ヴァンダ ファーマシューティカルズ インコーポレイテッ 概日リズム障害の治療
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CA2957588C (en) * 2014-09-02 2021-08-31 Vanda Pharmaceuticals Inc. Tasimelteon for treating smith-magenis syndrome
KR102650321B1 (ko) * 2019-12-13 2024-03-21 반다 파마슈티칼즈, 인코퍼레이티드. 액체 타시멜테온 제형 및 이의 사용 방법

Also Published As

Publication number Publication date
ES2936833T3 (es) 2023-03-22
US10179119B2 (en) 2019-01-15
CA3124872A1 (en) 2016-03-10
US11266622B2 (en) 2022-03-08
PT3188727T (pt) 2023-01-30
CA2957588C (en) 2021-08-31
DK3188727T3 (da) 2023-02-06
US20170239210A1 (en) 2017-08-24
US20240293355A1 (en) 2024-09-05
CN116098887A (zh) 2023-05-12
KR20170048541A (ko) 2017-05-08
CA2957588A1 (en) 2016-03-10
NZ729901A (en) 2020-09-25
JP2020143159A (ja) 2020-09-10
WO2016036619A1 (en) 2016-03-10
EP3188727A1 (en) 2017-07-12
US20200237712A1 (en) 2020-07-30
AU2020239640B2 (en) 2020-11-05
SI3188727T1 (sl) 2023-03-31
JP2017526693A (ja) 2017-09-14
BR112017003644A2 (pt) 2017-11-28
AU2015312252B2 (en) 2020-07-02
FI3188727T3 (fi) 2023-02-20
KR20240015729A (ko) 2024-02-05
MX386150B (es) 2025-03-18
HRP20230070T1 (hr) 2023-03-17
EP4137129A1 (en) 2023-02-22
MX2017002796A (es) 2017-06-09
US20220133681A1 (en) 2022-05-05
CN106604726A (zh) 2017-04-26
EP3188727B1 (en) 2022-11-09
AU2020239640A1 (en) 2020-10-15
JP7252390B2 (ja) 2023-04-04
JP6903571B2 (ja) 2021-07-14
NZ765911A (en) 2023-08-25
US20190105297A1 (en) 2019-04-11
AU2015312252A1 (en) 2017-03-30
JP7132277B2 (ja) 2022-09-06
US10653665B2 (en) 2020-05-19
JP2022078291A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
GB201413701D0 (en) Process
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
GB201405800D0 (en) Process
GB201405210D0 (en) Process
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
IL252111B (en) Methods for treating patients with Prader-Willi syndrome or Smith-Magnis syndrome
GB201406890D0 (en) Process
GB201415862D0 (en) Process
GB201404468D0 (en) Process
GB201413340D0 (en) Process
SI3188727T1 (sl) Tasimelteon za zdravljenje Smith-Magenisovega sindroma
IL249475A0 (en) Methods for treating itching
GB201402950D0 (en) Process
PL3186013T3 (pl) Urządzenie do obróbki przedmiotów
GB201409126D0 (en) Process
GB201402782D0 (en) Process
GB201400137D0 (en) Process
GB201412406D0 (en) Process
GB201707225D0 (en) Engaging Apparatus
GB201414292D0 (en) Process
GB201411627D0 (en) Process
EP3148525C0 (en) CAFESTOL FOR TREATING DIABETES
GB201412656D0 (en) Process
GB201405209D0 (en) Process
GB201403057D0 (en) Process